[1] |
Shen K, Cui J, Wei Y, et al. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: a meta-analysis[J]. J Thorac Dis, 2018, 10(12):6636-6652.
doi: 10.21037/jtd.2018.11.72
pmid: 30746209
|
[2] |
Pacheco J, Bunn P A. Advancements in small-cell lung cancer: The changing landscape following IMpower-133[J]. Clin Lung Cancer, 2019, 20(3):148-160.
doi: S1525-7304(18)30356-5
pmid: 30686680
|
[3] |
Ouyang T, Cao Y, Kan X, et al. Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review[J]. Front Oncol, 2021, 11:621639.
doi: 10.3389/fonc.2021.621639
URL
|
[4] |
Park R, Lopes L, Cristancho C R, et al. Treatment-rela-ted adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis[J]. Front Oncol, 2020, 10:258.
doi: 10.3389/fonc.2020.00258
URL
|
[5] |
Zhai Y, Ye X, Hu F, et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system[J]. J Immunother Cancer, 2019, 7(1):286.
doi: 10.1186/s40425-019-0754-2
pmid: 31694698
|
[6] |
Di Dalmazi G, Ippolito S, Lupi I, et al. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment[J]. Expert Rev Endocrinol Metab, 2019, 14(6):381-398.
doi: 10.1080/17446651.2019.1701434
pmid: 31842671
|
[7] |
Mizukoshi T, Fukuoka H, Takahashi Y. Immune checkpoint inhibitor-related hypophysitis[J]. Best Pract Res Clin Endocrinol Metab, 2022, 36(3):101668.
doi: 10.1016/j.beem.2022.101668
URL
|
[8] |
Bernhardt E B, Jalal S I. Small cell lung cancer[J]. Cancer Treat Res, 2016, 170:301-322.
doi: 10.1007/978-3-319-40389-2_14
pmid: 27535400
|
[9] |
Li LY, Wang H, Chen X, et al. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China[J]. Chin Med J (Engl), 2019, 132(23):2790-2794.
|
[10] |
Ott P A, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study[J]. J Clin Oncol, 2017, 35(34):3823-3829.
doi: 10.1200/JCO.2017.72.5069
pmid: 28813164
|
[11] |
Peng M, Li X, Lei G, et al. The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis[J]. Onco Targets Ther, 2018, 11:7369-7383.
doi: 10.2147/OTT
URL
|
[12] |
Ready N, Farago A F, De Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032[J]. J Thorac Oncol, 2019, 14(2):237-244.
doi: S1556-0864(18)33181-2
pmid: 30316010
|
[13] |
Horn L, Mansfield A S, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229.
doi: 10.1056/NEJMoa1809064
URL
|
[14] |
Kanie K, Iguchi G, Bando H, et al. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome[J]. Cancer Immunol Immunothe, 2021, 70(12):3669-3677.
doi: 10.1007/s00262-021-02955-y
|
[15] |
Ohara N, Kobayashi M, Ohashi K, et al. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature[J]. J Med Case Rep, 2019, 13(1):88.
doi: 10.1186/s13256-019-2002-2
|
[16] |
Takaya K, Sonoda M, Fuchigami A, et al. Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer[J]. Intern Med, 2017, 56(18):2463-2469.
doi: 10.2169/internalmedicine.8548-16
URL
|
[17] |
Mishima Y, Fukaishi T, Inase N, et al. Nivolumab-induced hypophysitis, secondary adrenal insufficiency and destructive thyroiditis in a patient with lung adenocarcinoma[J]. Intern Med. 2019 Mar 1;58(5):693-697.
|
[18] |
Valecha G, Pant M, Ibrahim U, et al. Immunotherapy-induced autoimmune hypophysitis[J]. J Oncol Pharm Pract, 2019, 25(1):217-220.
doi: 10.1177/1078155217727142
pmid: 28825378
|
[19] |
Kanie K, Iguchi G, Bando H, et al. Two cases of atezolizumab-induced hypophysitis[J]. J Endocr Soc, 2017, 2(1):91-95.
doi: 10.1210/js.2017-00414
URL
|
[20] |
Martins Machado C, Almeida Santos L, Barroso A, et al. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency[J]. BMJ Case Rep, 2019, 12(8):e231236.
doi: 10.1136/bcr-2019-231236
URL
|
[21] |
Yamagata S, Kageyama K, Takayasu S, et al. Progression of hypopituitarism and hypothyroidism after treatment with pembrolizumab in a patient with adrenal metastasis from non-small-cell lung cancer[J]. Intern Med, 2019, 58(24):3557-3562.
doi: 10.2169/internalmedicine.3008-19
URL
|
[22] |
Sato Y, Tanaka Y, Hino M, et al. A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency[J]. Respir Med Case Rep, 2019, 26:223-226.
doi: 10.1016/j.rmcr.2019.01.021
pmid: 30740300
|
[23] |
Zhu Y, Wu HH, Wang W. A case of small-cell lung cancer with adrenocorticotropic hormone deficiency induced by nivolumab[J]. Onco Targets Ther, 2019, 12:2181-2186.
doi: 10.2147/OTT
URL
|
[24] |
Fernandes S, Varlamov E V, Mccartney S, et al. A novel etiology of hypophysitis: immune checkpoint inhibitors[J]. Endocrinol Metab Clin North Am, 2020, 49(3):387-399.
doi: 10.1016/j.ecl.2020.05.002
URL
|
[25] |
中华医学会内分泌学分会免疫内分泌学组. 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J]. 中华内分泌代谢杂志, 2021, 37(1):1-16.
|
|
Immune-endocrinology Group, Chinese Society of Endocrinology, Chinese Medical Association. Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events (2020)[J]. Chin J Endocrinol Metab, 2021, 37(1):1-16.
|
[26] |
Paschou S A, Stefanadi K, Psaltopoulou, et al. How we treat endocrine complications of immune checkpoint inhibitors[J]. ESMO Open, 2021, 6(1):100011.
doi: 10.1016/j.esmoop.2020.100011
URL
|
[27] |
Shaverdian N, Lisberg A E, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903.
doi: S1470-2045(17)30380-7
pmid: 28551359
|
[28] |
España S, Pérez Montes de OCA A, Marques-pamies M, et al. Endocrine adverse events related to immune-onco-logy agents: retrospective experience of a single institution[J]. Transl Lung Cancer Res, 2020, 9(1):103-110.
doi: 10.21037/tlcr
URL
|